Skip to main content

01.10.2010 | Translational Research and Biomarkers | Ausgabe 10/2010

Annals of Surgical Oncology 10/2010

Clinical Significance of Stanniocalcin 2 as a Prognostic Marker in Gastric Cancer

Annals of Surgical Oncology > Ausgabe 10/2010
MD Takehiko Yokobori, MD Koshi Mimori, MD Hideshi Ishii, MD Masaaki Iwatsuki, MD Fumiaki Tanaka, MD Yukio Kamohara, MD Keisuke Ieta, MD Yoshiaki Kita, MD Yuichiro Doki, MD Hiroyuki Kuwano, MD, FACS Masaki Mori
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1245/​s10434-010-1086-0) contains supplementary material, which is available to authorized users.



Stanniocalcins are glycoprotein hormones that were originally found in the endocrine gland of bony fish. Microarray expression data from 32 paired samples of gastric cancer and normal mucosa in a public microarray database showed that the expression level of Stanniocalcin 2 was higher in gastric cancer than in normal gastric mucosa. The clinical significance of Stanniocalcin 2 expression has been observed for several cancers. However, the relationship between Stanniocalcin 2 and clinicopathological factors in gastric cancer has not yet been investigated.

Materials and Methods

We examined the clinical significance of Stanniocalcin 2 in gastric cancer in 108 gastric cancer samples using real-time reverse transcription-polymerase chain reaction (RT–PCR). Immunohistochemical studies were conducted with paraffin sections. The suppression analysis of Stanniocalcin 2 using siRNA was done to determine Stanniocalcin 2’s biological roles.


The level of Stanniocalcin 2 in cancer tissues was higher than in normal tissues (P = .0002). The high Stanniocalcin 2 expression group (n = 54) had more progressive lymph node metastasis (P = .07) and venous invasion (P = .028) than the low-expression group (n = 54). High Stanniocalcin 2 expression was an independent prognostic factor in gastric cancer patients (P = .02). Moreover, siRNA suppression of Stanniocalcin 2 in a gastric cancer cell line inhibited cellular proliferation (P < .05).


The high expression level of Stanniocalcin 2 in gastric cancer tissues could be a very powerful marker of poor prognosis. Therefore, Stanniocalcin 2 is a promising candidate for a molecular target for the treatment of gastric cancer.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Supplementary material 1 (EPS 1475 kb) Supplementary Figure A STC2 expression levels in 32 gastric cancer tissues from GSE13911. We examined dataset GSE13911, which comprised 32 pairs of normal and tumor samples. The probe sets that were flagged as “ABSENT” in all samples were removed before the data was analyzed. A total of 3613 genes were differentially expressed between the normal and tumor groups using the criteria of at least 1.5-fold variation and a false discovery rate (FDR) < 0.05 applied to the paired t test P values. STC2 was identified as highly expressed in gastric cancer tissues. The red line indicates the processed signal of STC2
Supplementary material 2 (XLS 525 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 10/2010

Annals of Surgical Oncology 10/2010 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.